> Chemicals & Drugs > Organic Chemical > Latanoprost

Latanoprost

Latanoprost is a synthetic prostaglandin F2α analogue used to treat elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.
It works by increasing the outflow of aqueous humor, leading to reduced intraocular pressure.
Latanoprost is typically administered as eye drops once daily and has been shown to be effective in lowering intraocular pressure over a 24-hour period.
Reseach on optimizing Latanoprost protocols can be facilitated by PubCompare.ai, a tool that helps users find the best protocols from literature, pre-prints, and patents to improve reproducibility and accuracy in Latanoprost research.
This AI-driven comparision tool can take your Latanoprost research to the next leve.

Most cited protocols related to «Latanoprost»

Evaluation of Eye Drops Quality and Safety

Cited 3 times

In order to demonstrate the applicability of our method we have selected a therapeutic drug category that we thought to have higher patient safety risk when purchased outside the closed drug supply chain. Their compromised quality, inappropriate use or misuse may lead to local or systemic health consequences (Kadri et al., 2010 , Morales et al., 2016 (link), Vaajanen and Vapaatalo, 2017 (link), Gao et al., 2018 (link)).
Ten commonly used eye drops available in community pharmacies throughout Hungary were selected as model products to illustrate the tool. Various medications, including prescription-only and over-the-counter products and eye drops with supply disruptions were included in our study sample. The characteristics of the selected products were also diverse, including eye drops used in the treatment of glaucoma, allergy, infection, or used for diagnostic procedures (mydriasis). The selected products are highlighted in Table 1.Table 1

The brand name and active ingredients of the ten selected eye drops.

Product brand name (Hungarian)	Active pharmaceutical ingredient
BETOPTIC 5 mg/ml (eye drop)	Betaxolol
AZOPT 10 mg/ml (suspension eye drop)	Brinzolamide
CILOXAN 3 mg/ml (eye and ear drop)	Ciprofloxacin
ALLEOPTI 20 mg/ml (eye drop)	Sodium cromoglicate
HUMAPENT 5 mg/ml (eye drop)	Cyclopentolate
SPERSALLERG 0.5 mg/ml + 0.4 mg/ml (eye drop)	Antazoline & tetryzoline
VISINE CLASSIC 0.5 mg/ml (eye drop)	Tetryzoline
COSOPT UNO 20 mg/ml + 5 mg/ml (single dose eye drop)	Dorzolamide & timolol
XALACOM 0.05 mg/ml + 5 mg/ml (eye drop)	Latanoprost & timolol
TRAVATAN 40 µg/ml (eye drop)	Travoprost

Vida R.G., Merczel S., Jáhn E, & Fittler A. (2020). Developing a framework regarding a complex risk based methodology in the evaluation of hazards associated with medicinal products sourced via the internet. Saudi Pharmaceutical Journal : SPJ, 28(12), 1733-1742.

Publication 2020

Allergic Reaction Antazoline Antiglaucoma Agents dorzolamide Drugs, Non-Prescription Infection Latanoprost Mydriasis Ophthalmic Solution Patient Safety Pharmaceutical Preparations Sodium Tests, Diagnostic Therapeutics Travoprost

ASBT Inhibition Screening of Diverse Compounds

Cited 3 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010

Atropine Bendroflumethiazide Buffers Bumetanide Cells Cell Survival Dibucaine Diltiazem Hydrochloride Fluvastatin Hanks Balanced Salt Solution Isradipine Ketoprofen Kinetics Latanoprost Madin Darby Canine Kidney Cells Membrane Transport Proteins Nitrendipine Pentamidine Isethionate Permeability Pharmaceutical Preparations Propafenone Psychological Inhibition Right Atrial Isomerism Simvastatin Sodium Sulfoxide, Dimethyl Taurocholate Thiothixene tioconazole Tissue Donors Torsemide

Transconjunctival Sutureless Vitrectomy Outcomes

Cited 2 times

A retrospective observational study was performed on 635 patients in a tertiary hospital in South India who underwent transconjunctival sutureless vitrectomy (TSV), 23-gauge type, using the Constellation vitrectomy surgical system. All surgeries were performed by a single surgeon, over a period of 36 months from years 2013 to 2015. Patient ages ranged from 12 to 95 years and there were 366 males and 269 females in the study. Data was collected from the Electronic Medical Records and Operation Theatre registers. A thorough clinical examination was performed preoperatively. The IOP was measured by a calibrated non-contact tonometer preoperatively and postoperatively on day 1, day 7, 1 month, 3 months, 6 months and 1 day and 1 month following silicone oil removal. Gonioscopy was done if needed.
Indications for TSV included retinal detachment, complications of proliferative diabetic retinopathy, epiretinal membrane, and macular hole. Other causes like a nucleus or intraocular lens drop, vitreous hemorrhage, or asteroid hyalosis were grouped as “Others.“ Silicone oil, air, or gas was implanted into the vitreous at the end of TSV or other combinations of surgeries, such as phaco fragmentation, or secondary IOL implantation. We did not include 20-gauge surgery in the study as it was not done during this time period.
In surgeries involving gas, 18% SF6 (sulphur hexafluoride) was used. Silicone Oil was removed about 4--6 months after implantation. IOP less than 20 mm Hg was predefined as normal.
To exclude pre-existing glaucoma 20 eyes were excluded from the study.
IOPs up to 25 mmHg were observed. Beta-blocker eye drops (timolol maleate 0.5%) was used if IOPs were over 25 mmHg. IOPs over 30 mmHg were treated with topical prostaglandin analogues (latanoprost), topical carbonic anhydrase inhibitors (dorzolamide), and beta-blockers (timolol maleate 0.5%). Oral acetazolamide was added to topical medications if IOPs were over 40 mmHg after ruling out contraindications. A peripheral iridotomy was additionally performed in event of a shallow anterior chamber or pupillary block.

Pillai G.S., Varkey R., Unnikrishnan U.G, & Radhakrishnan N. (2020). Incidence and risk factors for intraocular pressure rise after transconjunctival vitrectomy. Indian Journal of Ophthalmology, 68(5), 812-817.

Publication 2020

Acetazolamide Adrenergic beta-Antagonists Carbonic Anhydrase Inhibitors Cell Nucleus Chambers, Anterior Complications of Diabetes Mellitus Diabetic Retinopathy dorzolamide Epiretinal Membrane Eye Eye Drops Females Glaucoma Gonioscopy Latanoprost Lens Implantation, Intraocular Macular Holes Males Operative Surgical Procedures Ovum Implantation Patients Pharmaceutical Preparations Physical Examination Prostaglandins, Synthetic Pupil Retinal Detachment Retinal Diseases Silicone Oils Sulfur Hexafluoride Surgeons Timolol Maleate Vitrectomy Vitreous Hemorrhage

Measuring Intraocular Pressure in Mice

Cited 2 times

IOP was measured in conscious mice using a handheld rebound tonometer (Icare TonoLab; Colonial Medical Supply, Franconia, NH). For IOP measurements, the tonometer was held perpendicular to the cornea following the manufacturer's instructions. For each time-point, three sequential but independent readings were obtained and averaged. For each independent reading, the tonometer takes six readings, discards the highest and lowest values, and shows the average of the remaining four values as a single IOP measurement. For each experiment, a second laboratory member who was masked to treatment groups checked IOP at multiple points to ensure accurate data collection.
For wild-type mouse experiments, baseline IOP measurements were recorded for two days, and then mice were randomized to one of six treatment groups (n = 6 per group): 1) latanoprost-free acid (LFA; 10⁻⁴ M; Cayman Chemical, Ann Arbor, MI) alone; 2) STC-1 (2.5 μg/μL; Biovender Research and Diagnostic Products-Czech Republic) alone; 3) FP receptor inhibitor AL-8810 (10 mM; Sigma Aldrich, St. Louis, MO) alone; 4) LFA + STC-1; 5) LFA + AL-8810; or 6) STC-1 + AL-8810. In all cases, the contralateral eye was treated with vehicle (PBS for STC-1; dilution of dimethyl sulfoxide (DMSO) 1:1000 in PBS for LFA, dilution of DMSO 1:2.5 in PBS for AL-8810). Mice were treated once daily in the morning with topical instillation of 5 μL of medication for five consecutive days followed by three days of washout in which the animals received no treatment. In cases where an animal was treated with more than one drug, the first drug was applied and the second drug was given 10 minutes later. For receptor inhibition experiments, AL-8810 was given first followed by LFA or STC-1. IOP was measured three times daily at 1, 4, and 23 hours post-treatment. The 3 IOP measurements were averaged and reported as the daily IOP. A second laboratory member who was masked to treatment groups checked IOP at multiple points during the experiment to ensure accurate data collection.
In experiments utilizing FP receptor knockout mice, IOP was measured for 4 consecutive days to obtain baseline IOP values. FP receptor knockout mice (n = 7) and C57BL/6J wild-type controls (n = 7) were treated for 6 consecutive days with topical LFA (5 μL of a 10⁻⁴ M solution) followed by cessation of treatment for 5 days. With IOP at baseline, the same mice were treated with STC-1 (5 μL of a 0.5 μg/μL solution) once daily for 6 consecutive days followed by a final 3 day washout period. IOP was measured twice daily at 1 and 23 hours post treatment. Daily IOP measurement was reported as the average of the 1 and 23 hour IOP reading. Longitudinal data is presented as change in IOP compared to the fellow eye.

Roddy G.W., Rinkoski T.A., Monson K.J., Chowdhury U.R, & Fautsch M.P. (2020). Stanniocalcin-1 (STC-1), a downstream effector molecule in latanoprost signaling, acts independent of the FP receptor for intraocular pressure reduction. PLoS ONE, 15(5), e0232591.

Publication 2020

Acids AL 8810 Animals ARID1A protein, human Caimans Consciousness Cornea Diagnosis Latanoprost Lymphocyte Function-Associated Antigen-1 Mice, Knockout Mus Pharmaceutical Preparations prostanoid FP receptor Psychological Inhibition STC1 protein, human Sulfoxide, Dimethyl Technique, Dilution Withholding Treatment

Glaucoma Diagnosis and Latanoprost Treatment

Cited 2 times

Glaucoma was diagnosed using a visual field test (Humphrey Visual Field Analyzer 30–2 standard program; Carl Zeiss, Jena, Germany) and optical coherence tomography (OCT; RC3000; Nidek, Gamagori, Japan), which was used to measure the thickness of the ganglion cell complex. Routine ophthalmological examinations were also performed. Subjects with POAG and NTG were screened for eligibility with a battery of ophthalmic examinations including slit-lamp biomicroscopy, funduscopy, gonioscopy, IOP measurements, and visual field analysis using the 30–2 Swedish Interactive Threshold Algorithm standard strategy (Carl Zeiss, Jena, Germany). POAG and NTG were diagnosed when the following three conditions were present: (1) glaucomatous optic cupping represented by notch formation, generalized enlargement of cupping, senile sclerotic disc or myopic disc, or nerve fiber layer defects, (2) reproducible typical glaucomatous visual field defects such as Bjerrum scotoma, nasal step, or paracentral scotoma compatible with optic disc appearance, and (3) open angle observed on gonioscopy or slit-lamp biomicroscopy.
Topical glaucoma medications were Xalatan (0.005% latanoprost; Pfizer, Tokyo, Japan) and Xalacom (fixed combination with 0.005% latanoprost and 0.5% timolol maleate; Pfizer, Tokyo, Japan). One of the authors (MA) examined all glaucoma patients and controls, and reviewed medical records to check patient compliance by confirming the frequency and duration of visits, and the amount of prescribed latanoprost. Six months of latanoprost use was a sufficient period since previous studies [16 (link),19 ] observed participants for 1 and 30 days to confirm significant effects.
Evaluation of control subjects included best-corrected visual acuity measurements, autorefractometry, slit-lamp biomicroscopy, funduscopy, and IOP measurements with a noncontact tonometer or Goldmann applanation tonometer. This group consisted mostly of individuals who visited the clinic for annual eye examinations, or who had an outer adnexal disease.
Binocular near add power was measured by a blinded examiner at a distance of 30 cm using a Bankoku near-acuity chart (Handaya Inc., Tokyo, Japan) or an automatic optometry system (AOS-700; Nidek, Gamagori, Japan). After determining the patient's distance refractive correction, the minimal additional power required to achieve near acuity better than 20/25 was measured in 0.25 D increments and was recorded as near add power.

Ayaki M., Tsuneyoshi Y., Yuki K., Tsubota K, & Negishi K. (2019). Latanoprost could exacerbate the progression of presbyopia. PLoS ONE, 14(1), e0211631.

Publication 2019

Adnexal Diseases Eligibility Determination Ganglia Glaucoma Glaucoma, Primary Open Angle Gonioscopy Hypertrophy Latanoprost Myopia Nerve Fibers Nose Ocular Refraction Ophthalmoscopy Optic Disk Patients Pharmaceutical Preparations Physical Examination Sclerosis Slit Lamp Examination Timolol Maleate Tomography, Optical Coherence Visual Acuity Visual Field Tests Xalacom Xalatan

Most recents protocols related to «Latanoprost»

Comparative Effectiveness of KDB Goniotomy and Trabectome

This was a retrospective chart review comparing all patients undergoing KDB goniotomy between January 2016 and March 2020 at New York Eye and Ear Infirmary of Mount Sinai and Trabectome between January 2013 and December 2019 at Yale Eye Center, both in combination with cataract surgery. This study was approved by the Mount Sinai Institutional Review Board (IRB) (IRB-20-03241) and the Yale IRB (IRB-2000026321). Patient consent to review medical records was not required by the Mount Sinai IRB and the Yale IRB, as the use or disclosure of patient health information involved no more than a minimal risk to the privacy of individuals. All efforts were made to maintain patient data confidentiality including use of an encrypted local database and an adequate plan to destroy patient identifiers at the earliest opportunity consistent with the conduct of research. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Data were collected from subjects aged 18 years or older with at least 1 month of follow-up after surgery. All glaucoma subtypes and severities were included, along with patients with history of selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT). Exclusion criteria included age less than 18 years, having prior intraocular surgery, and having additional glaucoma surgery performed at the time of KDB or Trabectome with cataract surgery or within 12 months of the initial surgery.
Patient demographics and pre-operative characteristics were gathered. Visual acuity was evaluated via Snellen chart, intraocular pressure (IOP) via Goldmann applanation tonometry, visual fields via 24–2 Humphrey visual field, anterior segment via slit-lamp examination, and posterior segment via dilated fundus examination. Medication regimens were determined at the discretion of each surgeon but included the following medications: bimatoprost, brimonidine, brinzolamide, dorzolamide, latanoprost, methazolamide, netarsudil, pilocarpine, tafluprost, timolol, travoprost, and unoprostone. IOP and number of medications were collected from the visits closest to post-operative month 1 (POM1), month 6 (POM6), and month 12 (POM12) following surgery. Complications including hyphema, IOP elevation greater than 10 mmHg above pre-operative value, ciliary body detachment, hypotony, aqueous misdirection, wound leak, and postoperative infection were recorded. Hyphema was defined as either dispersed or layering and was recorded on post-operative day 1 (POD1). All grades of hyphemas including microhyphema were recorded. Anticoagulation use was recorded categorically in patients taking acetylsalicylic acid, clopidogrel, direct oral anticoagulants, or warfarin. Chart documentation was completed by each individual surgeon. The Enhanced Glaucoma Severity Staging system was used to grade severity.13 (link) Success was defined as an IOP <21 mmHg and at least 20% reduction in IOP at POM12.

Fliney G.D., Kim E., Sarwana M., Wong S., Tai T.Y., Liu J., Sarrafpour S., Chadha N, & Teng C.C. (2023). Kahook Dual Blade versus Trabectome (KVT): Comparing Outcomes in Combination with Cataract Surgery. Clinical Ophthalmology (Auckland, N.Z.), 17, 145-154.

Publication 2023

Anticoagulants Argon Ion Lasers Aspirin Bimatoprost Brimonidine brinzolamide Cataract Extraction Ciliary Body Clopidogrel dorzolamide Ethics Committees, Research Glaucoma Goniotomy Homo sapiens Hyphema Infection Latanoprost Methazolamide netarsudil Ocular Hypotension Operative Surgical Procedures Patients Pharmaceutical Preparations Pilocarpine Slit Lamp Examination Surgeons tafluprost Timolol Tonometry, Ocular Trabeculectomy Travoprost Treatment Protocols Visual Acuity Warfarin Wounds

Intradermal Injection of Prostaglandin Analogues

Unfortunately, neither PGE2 nor PGF2a is available in Egypt as injection formula. PGE2 ‏is commercially available as dinoprostone vaginal tablets 3 mg, (Prostin E2, Pfizer, Sanico NV, Turnhout, Belgium). To prepare solution suitable for intradermal injection, each tablet was transformed into powder in a separate vial, and then disinfected by Cobalt-60 gamma radiation. During treatment session, each vial was dissolved with 12 ml saline; each 1 mL of it contains 250 μg of dinoprostone. It was stored at 2–8 °C for a maximum of 2 weeks. PGF2α is commercially available as Latanoprost 0.005% (Xalatan eye-drop formulation 2.5ml; Pfizer Manufacturing, Puurs, Belgium). Each 1 mL of Xalatan contains 50 μg of latanoprost. It was stored at 2–8 °C. According to Eldelee et al. [8 (link)], PGF2α eye-drop was injected intradermally as such without any dilution. Once opened, the container was stored at room temperature below 25 °C away from direct light, for a maximum of 4 weeks.

Neinaa Y.M., Mahmoud M.A., El Maghraby G.M, & Ibrahim Z.A. (2023). Efficacy of prostaglandin E2 versus prostaglandin F2 alpha assisted with narrowband-UVB in stable vitiligo. Archives of Dermatological Research, 315(9), 2647-2653.

Publication 2023

Cobalt-60 Dinoprost Dinoprostone Eye Drops Gamma Rays Intradermal Injection Latanoprost Light Powder Saline Solution Tablet Technique, Dilution Vaginal Tablet Xalatan

Corneal Healing Impacts of Latanoprost Formulations

The influences of preserved and PF latanoprost (50 µg/ml)-containing eyedrops on the market were firstly investigated in a study over 3 days on the efficacy of corneal healing. Based on the findings of this study, a follow-up study with prolonged exposure and observation time was conducted with PF latanoprost preparations only. For details of the latanoprost formulations, please refer to Table 1.Table 1

Ingredients of latanoprost test item formulations

	Formulation A(Xiop®- Xalof®)	Formulation B(Latazed® formulation)	Formulation C(Monoprost®)	Formulation X(Xalatan®)
Active substance	Latanoprost 0.005%	Latanoprost 0.005%	Latanoprost 0.005%	Latanoprost 0.005%
Preservative	–	–	–	BAC 0.02%
Surfactant	–	MGHS 2.5%	MGHS 5%	–
Thickening agents	–	–	Macrogol 4000, carbomer 974P	–
pH buffer	H₄NaO₅P, Na₂HPO₄	H₄NaO₅P, Na₂HPO₄	NaOH	H₄NaO₅P, Na₂HPO₄
Other excipients	NaCl, WFI	Disodium EDTA, NaCl, WFI	Disodium EDTA, sorbitol, WFI	NaCl, WFI

MGHS macrogolglycerol hydroxystearate 40, H₄NaO₅P sodium dihydrogen phosphate monohydrate, Na₂HPO₄ disodium hydrogen phosphate anhydrous, NaCl sodium chloride, NaOH sodium hydroxide, BAC benzalkonium chloride, WFI water for injection

For the 3-day study, we tested all formulations compared to 0.02% BAC and to PF hyaluronic acid 0.18% eyedrops (control reference; CT). For the 5-day study, only the PF eyedrops (formulations A, B and C) were examined. They include different MGHS concentrations with 5% being the highest. Thus, a single-component 5% MGHS 40 solution was used as a control diluted with distilled water + NaCl. The CT was also used as the control reference.
All test substances were applied directly by dripping a volume of 30–50 µl six times daily onto the apex of controlled epithelial injured corneas. This high frequency application model allows one to mimic the chronic use of treatment in long-term diseases such as glaucoma. The experimental approaches were carried out in triplicate (3-day study) or quintuplicate (5-day study). The osmotic pressure (Osmomat 3000, Gonotec, Berlin, Germany) and the pH (pH 1000 H, pHenomenal®, VWR, Germany) of all used formulations were measured before the treatments. These were in the physiological range around pH 6–7 and around 300 mosmol/kg, except for the hypoosmotic control substance CT (162 mosmol/kg).

Panfil C., Chauchat L., Guerin C., Rebika H., Sahyoun M, & Schrage N. (2023). Impact of Latanoprost Antiglaucoma Eyedrops and Their Excipients on Toxicity and Healing Characteristics in the Ex Vivo Eye Irritation Test System. Ophthalmology and Therapy, 12(5), 2641-2655.

Publication 2023

carbomer Chloride, Benzalkonium Cornea Edetic Acid Eye Drops Glaucoma Hyaluronic acid Latanoprost Osmotic Pressure Pharmaceutical Preservatives physiology polyethylene glycol 4000 Sodium Chloride Sodium Hydroxide sodium phosphate, dibasic sodium phosphate, monobasic Sorbitol Surface-Active Agents Xalatan

Comparing SLT and Latanoprost for Glaucoma Treatment

This single-center, prospective, randomized clinical trial was conducted between December 2018 and June 2021. All measurements (visual field, optic disc imaging, and IOP) were made by research team members masked to treatment allocation. Clinicians and patients were not masked in treatment allocation. Using a web-based system, we randomly assigned patients (1:1) to either SLT or 0.005% latanoprost as first-line treatment (www.sealedenvelope.com). This trial was approved by the ethical committees of the Eye Hospital, China Academy of Chinese Medical Sciences. All participants provided informed consent before study enrollment. The study was registered at www.chictr.org.cn (registration number ChiCTR2200056850) and complied with the principles outlined in the Declaration of Helsinki²².

Shi Y., Zhang Y., Sun W., Huang A.S., Chen S., Zhang L., Wang W., Xie L, & Xie X. (2023). 24-Hour efficacy of single primary selective laser trabeculoplasty versus latanoprost eye drops for Naïve primary open-angle glaucoma and ocular hypertension patients. Scientific Reports, 13, 12179.

Publication 2023

Chinese Latanoprost Optic Disk Patients

Comparative Study of SLT vs. Latanoprost for POAG

Patients seen at the glaucoma department of the Eye Hospital, China Academy of Chinese Medical Sciences, were screened for eligibility. POAG was defined as angles open on the gonioscopy and optic disc or retinal nerve fiber layer (RNFL) structural abnormalities corresponding to visual field (VF) loss without secondary causes. OHT was defined as an IOP of more than 21 mm Hg without glaucomatous optic nerve structural and functional changes. POAG was classified as high-tension glaucoma (HTG) and normal-tension glaucoma (NTG). Both types exhibited open angles, but HTG was characterized by an IOP higher than 21 mm Hg without treatment, while NTG had an IOP lower than 21 mm Hg on multiple clinic visits or peak measurements before treatment^{23 (link)}. Glaucoma severity stratification (mild, moderate, or severe) was determined using visual field mean deviation (VF MD) at baseline, according to Mills et al.^{24 (link)}. The values of VF MD in mild, moderate, and severe POAG were more than − 6 decibels (dB), − 6 to − 12 dB, and lower than − 12 dB, respectively. Inclusion and exclusion criteria were adopted to improve diagnosis accuracy and reduce potential bias induced by confounding factors. Inclusion criteria included: (a) patients newly diagnosed with OHT, mild POAG, or moderate POAG; (b) VF MD better than − 12 dB in the study eye; (c) age ≥ 18 years; (d) no history of glaucoma medications use in either eye for ≥ four weeks; and (e) willingness to undergo SLT versus latanoprost eye drops treatment. Exclusion criteria included: (a) VF MD worse than − 12 dB in the study eye; (b) patients with narrow angles or secondary glaucoma; (c) those with very high IOP who need immediate treatment (IOP > 30 mm Hg, initially or after washout); (d) any ocular condition precluding visualization of the TM; (e) previous anterior segment surgery or glaucoma laser; and (f) pregnancy. When both of a patient's eyes met the inclusion and exclusion criteria, they were given either SLT or latanoprost therapy. However, only the data from the right eye was considered for analysis^{25 (link)}.

Publication 2023

BAD protein, human Chinese Clinic Visits Congenital Abnormality Eligibility Determination Eye Drops Glaucoma Glaucoma, Primary Open Angle Gonioscopy Latanoprost Low Tension Glaucoma Nerve Fibers Operative Surgical Procedures Optic Disk Optic Nerve Patients Pharmaceutical Preparations Pregnancy Retina Therapeutics Vision

Top products related to «Latanoprost»

Xalatan by Pfizer

Sourced in United States, France

Xalatan is a laboratory equipment product manufactured by Pfizer. It is designed to perform specific functions within a laboratory setting. The core function of Xalatan is to facilitate the measurement and analysis of various samples and materials.

Latanoprost by Cayman Chemical

Sourced in United States

Latanoprost is a synthetic prostaglandin F2α analogue. It is a clear, colorless to slightly yellow oil.

Latanoprost by Pfizer

Sourced in Japan

Latanoprost is a synthetic prostaglandin analog used in the treatment of open-angle glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.

Lumigan by Abbvie

Sourced in United States

Lumigan is a laboratory equipment product designed for research and scientific applications. It functions as a precision tool for various laboratory procedures and experiments.

Travatan by Alcon

Sourced in United States

Travatan is a pharmaceutical product that is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It contains the active ingredient travoprost, which is a prostaglandin analog that increases the outflow of aqueous humor from the eye, thereby reducing the pressure within the eye.

Xalatan eye drops 0.005 by Pfizer

Sourced in Japan

Xalatan® eye drops 0.005% is a prescription eye drop medication manufactured by Pfizer. It contains the active ingredient latanoprost, which is a prostaglandin analog. The core function of Xalatan® is to reduce elevated intraocular pressure, which is a key risk factor for glaucoma.

Bimatoprost by Cayman Chemical

Sourced in United States

Bimatoprost is a synthetic prostaglandin analog compound. It is used as a laboratory reagent in research and development applications.

Cx41 light microscope by Olympus

Sourced in Japan, Germany

The Olympus CX41 is a light microscope designed for routine observation and analysis. It features LED illumination, an infinite optical system, and a quadruple nosepiece for multiple objectives. The CX41 provides clear, high-contrast images for a variety of applications.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Xalacom combination eye drops by Pfizer

Sourced in United States, Japan

Xalacom® is a combination eye drop product containing the active ingredients latanoprost and timolol maleate. It is designed for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

What are the common usage challenges with Latanoprost?

Latanoprost is generally well-tolerated, but some common usage challenges include: - Proper eye drop application technique is important to maximize effectiveness and minimize side effects. Applying the drops correctly can be tricky for some patients. - Latanoprost may cause some initial redness, irritation or stinging upon application. These side effects usually subside within the first few weeks of use. - Long-term use of Latanoprost can potentially lead to changes in eye color and increased eyelash growth, which may be undesirable for some patients.

Are there different variations or types of Latanoprost available?

Yes, there are a few different variations of Latanoprost available: - The original Latanoprost formulation is administered as a once-daily eye drop. - There is also a fixed-combination eye drop that contains Latanoprost plus another IOP-lowering medication like Timolol. - Newer sustained-release Latanoprost implants are being developed that can provide longer-lasting IOP reduction with less frequent dosing.

What are some specific applications of Latanoprost?

Latanoprost has a few key applications: - The primary use of Latanoprost is to treat elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. It helps lower IOP by increasing aqueous humor outflow. - Latanoprost may also be used off-label to treat other types of glaucoma, like normal-tension glaucoma, when other medications are not effective. - Some research indicates Latanoprost may have anti-fibrotic properties and could potentially be useful in certain eye surgeries to prevent scarring.

How can PubCompare.ai assist with optimizing Latanoprost use and research?

PubCompare.ai can really help with Latanoprost research and optimization in a few key ways: 1. It allows you to more efficiently screen the scientific literature on Latanoprost protocols and formulations. The AI-driven comparisons can pinpoin the key differences between protocols to identify the most effective options. 2. The platform's analytics can highlight critical insights that might otherwise be missed, such as which Latanoprost parameters or co-therapies lead to the best outcomes. This can guide your research towards the most promising approaches. 3. By identifying the optimal Latanoprost protocols, PubCompare.ai helps ensue your research is as reproducible and accurate as possible, savinr time and resources.

More about "Latanoprost"

Latanoprost is a synthetic prostaglandin F2α analogue that is commonly used to treat elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.
It works by increasing the outflow of aqueous humor, leading to reduced intraocular pressure.
Latanoprost is typically administered as eye drops once daily and has been shown to be effective in lowering intraocular pressure over a 24-hour period.
Research on optimizing Latanoprost protocols can be facilitated by PubCompare.ai, a powerful AI-driven tool that helps users find the best protocols from literature, pre-prints, and patents.
This tool improves reproducibility and accuracy in Latanoprost research by enabling users to compare and identify the most reliable and effective protocols.
Latanoprost is closely related to other ophthalmic medications like Xalatan, Lumigan, Travatan, and Xalcom, which are also prostaglandin analogues used to treat glaucoma and ocular hypertension.
Bimatoprost, another prostaglandin analogue, is also sometimes used in Latanoprost research.
Additionally, the CX41 light microscope and DMSO have been utilized in studies involving Latanoprost.
By leveraging the insights and capabilities of PubCompare.ai, researchers can take their Latanoprost studies to the next level, ensuring greater reproducibility, accuracy, and overall research quality.